Introduction
Mitral valve disease is the most common valvular disease in the developed countries and surgery is the gold standard treatment. 1, 2 Due to a massive shift from mechanical to bioprosthetic valves with finite longevity, increasing numbers of patients are presenting with bioprosthetic mitral valve degeneration. 3 Recurrent mitral regurgitation (MR) is frequent after mitral valve repair, particularly in the setting of functional MR. 4 Mitral valve reoperation often entails high risk due to age, multiple comorbidities, and hostile anatomy. In addition, patients with severe mitral annular calcification (MAC) associated with mitral valve disease are considered as poor candidates for traditional surgery due to technical challenges and high perioperative mortality. 5 Transcatheter mitral valve replacement (TMVR) is an emerging treatment for patients with severe mitral valve disease at high risk for conventional mitral valve surgery. Recent studies have demonstrated the efficacy and safety of TMVR for patients with degenerated bioprostheses, failed annuloplasty repair, and severe MAC. 6, 7 Nevertheless, currently used devices were designed for the aortic position and TMVR requires invasive transapical or complex transseptal approaches. Furthermore, the anatomical differences between mitral bioprosthetic valves, annuloplasty rings, and severely calcified mitral annulus lead to specific procedural challenges for each unique TMVR procedure. Identifying the predictors of adverse outcomes is essential as patients are selected and counselled regarding competing surgical and transcatheter options. In addition, the risk of bioprosthetic valve thrombosis is being increasingly recognized but limited data exists about thrombosis after TMVR. The lack of randomized trial data in this field highlights the importance of reporting outcomes from large-sample registries. Therefore, we created an international multicentre registry of TMVR to evaluate and compare TMVR associated procedural events and clinical outcomes.
Methods

Study design and patient population
The TMVR registry is an international, multicentre, observational study that enrolled consecutive patients undergoing TMVR for mitral degenerated bioprostheses [valve-in-valve (ViV)], failed annuloplasty rings [valve-
in-ring (ViR)], or severe MAC [valve-in-mitral annular calcification (ViMAC)]. The registry included 40 European and American centres and was initiated in November 2015. Patients were considered TMVR candidates if they had significant dysfunction (either stenosis, regurgitation, or both) of a bioprosthetic mitral valve, annuloplasty ring, or a calcified mitral annulus, with comorbid conditions that would preclude a conventional mitral valve surgery. The study was approved by the institutional review board of each institution when required; however, in some countries, for retrospective analysis of clinically acquired and anonymized data, the institutional review board waived the need for written patient informed consent.
Study devices and transcatheter mitral valve replacement procedures
Patients were selected for TMVR at the institutional level after discussions by the multidisciplinary heart team, and device type and access site were determined thereafter. Device size was selected based on a combination of the manufacture's reported diameter as well as multidetector row computed tomography and transoesophageal echocardiographic measurements. [8] [9] [10] The ViV software application was used to guide the [11] [12] [13] [14] [15] The sizes of transcatheter valves were categorized as previously described. 6 
Endpoints and definitions
The primary endpoints were all-cause mortality at 30 days and 1 year. Secondary endpoints were technical, device and procedural success, and other major clinical endpoints defined according to the Mitral Valve Academic Research Consortium (MVARC) criteria. 16 In the present study, we used modified criteria for significant mitral stenosis (MS) defined as a mean transmitral gradient > _10 mmHg and/or an effective orifice area < _1.0 cm 2 as previously described. 6 Bioprosthetic valve thrombosis was defined as valve dysfunction (mean transvalvular gradient > _10 mmHg and/or restricted leaflet motion with echocardiography) secondary to thrombosis diagnosed on the basis of response to anticoagulation or surgical findings.
Data collection
Data collection included baseline clinical, echocardiographic and procedural characteristics, and clinical follow-up data, at pre-specified time points (1, 6 , and 12 months and yearly thereafter). Follow-up was obtained by clinical visits and/or through telephone contacts. Referring cardiologists, general practitioners, and patients were contacted whenever necessary for further information. All data provided by each institution were anonymized and centrally collected, and all inconsistencies were resolved directly with local investigators. 10.1 ± 6.9%; P = 0.12) ( Table 1) . However, baseline characteristics significantly differed across the three groups: The patients in ViMAC group were more likely to be female and have New York Heart Association functional Class IV heart failure symptoms and chronic pulmonary disease, whereas patients in ViR group were more likely to have prior coronary artery bypass graft surgery (CABG) and myocardial infarction with lower left ventricular ejection fraction (LVEF). The predominant mechanism of failure was MR in the ViR group but MS was the most frequent form of valve dysfunction in the ViMAC group.
Statistical analysis
Procedural data
Procedural details are summarized in Table 2 . The majority of patients were treated via transapical access (59.5%) with the balloonexpandable Sapien valves (90.0%). The Sapien valves were more frequently used in the ViV group, whereas the large size device was more frequently used in the ViMAC group compared with ViV and ViR groups. Planned concomitant aortic valve replacement was performed in 20 patients (3.8%), more frequently with ViMAC compared with ViV and ViR (12.1% vs. 3.7% vs. 0.7%; P = 0.001). Balloon pre-and post-dilatation were more frequently performed in the ViMAC group compared with ViV and ViR groups. Contrast dose was the larger in the ViMAC group compared with the other two groups (64.8 ± 55.7 mL vs. 45.9 ± 66.5 mL vs. 36.5 ± 51.5 mL; P = 0.01), whereas fluoroscopic time was similar across the three groups.
Procedural outcomes
Procedural and 30-day outcomes are summarized in Table 3 .
Procedural complications varied significantly between the three ; P = 0.006), whereas alcohol septal ablation was more frequently performed in the ViMAC group than ViV and ViR groups (12.1% vs. 0.6% vs. 0.7%; P < 0.001). There were no significant differences in atrial septal defect closure and surgical mitral valve replacement between the three groups. Post-procedural LVEF remained lowest in the ViR group compared with ViV and ViMAC groups. Significant MS was only observed in seven patients (1.3%) of the entire cohort. Post-procedural MR > _moderate was more frequently observed in the ViR group compared with ViMAC and ViV groups (18.4% vs. 13 .8% vs. 5.6%; P < 0.001). Following the paravalvular leak closure, the rates of MR > _moderate at 30 days remained higher in ViMAC and ViR groups than the ViV group (13.2% vs. 12.6% vs. 3.3%; P < 0.001) (see Supplementary material online, Figure S1 ). Device success was the highest in the ViV group followed by ViR and ViMAC groups (84.8% vs. 69.5% vs. 53.4%; P < 0.001).
Clinical outcomes
All-cause 30-day mortality was the highest in the ViMAC group followed by the ViR and ViV groups (34.5% vs. 9 .9% vs. 6 .2%; P < 0.001). There were no significant differences in stroke and major or extensive bleeding between the three groups. Life-threatening or fatal bleeding tended to be more frequent in the ViR group, whereas major vascular complication and Stage 2 or 3 acute kidney injury occurred more frequently in the ViMAC group. Procedural success was highest in the ViV group followed by the ViR and ViMAC groups (73.6% vs. 57.4% vs. 41.4%; P < 0.001). In general, there were no significant differences in procedural complications between trans-septal and transapical approaches with the exceptions of higher rates of atrial septal defect closure and alcohol septal ablation and lower rate of life-threatening or fatal bleeding with trans-septal access (see Supplementary material online, Table S4 ). Patients were divided into early experience and late experience groups according to the median number of TMVR procedures at each institution. Compared with the early experience group, the late experience group had lower rates of conversion to surgery, 30-day mortality, life-threatening or fatal Figure S2A -C).
Mid-term mortality
Over a median follow-up period of 160 days (interquartile range 60-420 days), a total of 117 patients died in the overall cohort (53 patients in the ViV group, 34 patients in the ViR group, and 30 patients in the ViMAC group). The 1-year all-cause and cardiovascular mortality were 23.5% and 20.2% in the entire cohort, respectively ( Figure 1) . (Figure 2A and Supplementary material online, Figure S3 ). Landmark analysis showed higher late mortality (30-360 days) in the ViMAC group (43.2%) compared with the ViR (23.0%) and ViV groups (8.4%) ( Figure 2B) . Patients with postprocedural MR > _moderate had significantly higher 1-year all-cause mortality compared with those with MR < _mild (41.5% vs. 21 .4%; log rank P = 0.01) (Figure 3) . However, there was no significant difference in 1-year all-cause mortality between trans-septal and transapical approaches (see Supplementary material online, Figure S4 ). After adjustment with multivariable analysis, STS score, chronic pulmonary disease, pre-procedural status of mitral valve (ViV vs. ViR vs. ViMAC), and post-procedural MR > _moderate were independently associated with all-cause mortality in the entire cohort ( 
Thrombosis and anticoagulation
Information regarding antithrombotic prophylaxis and valve thrombosis was available in 411 patients (78.9%). Among them, 295 patients (71.8%) received anticoagulation therapy and the remaining 116 (28.2%) patients received antiplatelet therapy after TMVR (see Supplementary material online, Figure S5A ). During the entire followup, clinical thrombosis was observed in 10 patients after ViV (nine patients with stented porcine valves and one patient with a pericardial valve) and one patient after ViR but none after ViMAC. The timing of thrombosis varied significantly from within 24 h to 2 years after the index TMVR procedure (see Supplementary material online, Figure S5B ). At 1-year follow-up, the cumulative incidence of thrombosis was significantly higher in patients without anticoagulation compared with those with anticoagulation (6.6% vs. 1.6%; log-rank P = 0.019) (Figure 4) . 
Discussion
The major findings of the present study are as follows: (i) TMVR provided excellent outcomes for patients with degenerated bioprosthetic valves but TMVR for failed annuloplasty rings and MAC were associated with frequent procedural complications; (ii) patients with failed annuloplasty rings and severe MAC were at increased risk of mortality after TMVR; and (iii) valve thrombosis was more frequently observed after TMVR in patients without anticoagulation compared with those with anticoagulation. The present study is the largest TMVR registry published to date demonstrating procedural challenges and prognosis across different population. TMVR provided excellent outcomes for patients with degenerated bioprosthetic valves despite high surgical risk.
Procedural complications were observed in less than 3% of procedures, consistent with the previous reports. 17 The 30-day mortality after mitral ViV in the present study (6.2%) was acceptable considering the higher in-hospital and 30-day mortality after redo mitral valve surgeries (9.2-12.6%) in previously published studies. [18] [19] [20] As the present large study is consistent with recent reports with comparable early and mid-term mortality, TMVR is an attractive option for patients with degenerated bioprosthetic mitral valves. Transcatheter mitral valve replacement for patients with failed annuloplasty repair and severe MAC poses unique and serious procedural challenges, namely LVOT obstruction and post-procedural MR. Previous studies showed that LVOT obstruction occurred more frequently after ViMAC (7.4% to 17%) and ViR (13.3% to 20%) compared with ViV and was associated with increased 1-year The impact of significant residual MR on increased mortality and late adverse events has been widely recognized in patients undergoing surgical or transcatheter mitral valve repair. 25, 26 The present study identified significant post-procedural MR as an independent predictor of increased mortality after TMVR. The rates of MR > _moderate after ViR (18.4%) and ViMAC (13.8%) were suboptimal although post-procedural MR > _Grade 3 (moderate to severe) was modest (4.2% and 1.7%, respectively). The present study demonstrated improved major clinical outcomes with increased experience, but no significant improvements in LVOT obstruction and postprocedural MR were observed in the late experience group. Further clinical experience, better patient selection and advancement in device technology promise to improve TMVR outcomes. Increased mid-term mortality after ViR in the present study may be affected by frequent procedural complications as well as underlying mitral valve disease. Patients treated with ViR had more frequent prior CABG and myocardial infarction with lower LVEF, suggesting higher proportion of functional MR as the underlying aetiology of mitral valve disease. Since recurrence of MR after mitral valve repair was associated with increased long-term mortality, the potential benefit of ViR for severe MR may be confounded by advanced age, cardiac and non-cardiac comorbidities. 25, 27 The 30-day mortality in the present study (9.9%) was comparable to those after ViR from reported studies (6.7-11.4%), 22, 28 as well as those after redo mitral valve repair (9.0% and 9.2%). 19, 29 Nevertheless, relatively high rates of 1-year mortality after ViR in the present study (30.6%) should be cautiously interpreted. Recent study reported that the 1-year mortality rate after mitral valve reoperation of 23.1% , mainly related to high in-hospital mortality (12.6%). 20 Although direct comparison is difficult, landmark analysis in the present study showed higher late mortality after ViR (23.0%), suggesting the adverse impact of postprocedural MR in this population.
Patients with MAC associated with mitral valve disease experienced surprisingly higher early and mid-term mortality after TMVR (34.5% and 62.8%, respectively). Notably, these mortality rates were comparable to those reported recently by Guerrero et al. 7 (25.0%
and 53.7%). As LVOT obstruction and post-procedural MR contribute to the increased mortality, every effort should be made to predict and prevent these serious complications with dedicated imaging analysis. Given high late mortality (43.2%) shown by landmark analysis in patients with MAC, appropriate patient selection is essential to avoid futile TMVR procedures. Bioprosthetic valve thrombosis is a multifactorial phenomenon affected by anatomic, procedural, and pharmacological factors. 30 The risk of valve thrombosis is higher in the mitral position than the aortic position, highest in the first few months after implantation, and may continue thereafter. In the present study, the majority of thrombosis (90.9%) was observed after mitral ViV. Interestingly, the valve thrombosis was more frequently observed in previous porcine valves (nine patients) compared with pericardial valves (one patient), consistent with previous surgical aortic valve replacement and aortic valve-invalve publications. 31, 32 The lower rate of thrombosis in patients with anticoagulation compared with those without anticoagulation suggests that anticoagulant thromboprophylaxis may be beneficial, particularly for the first few months after TMVR procedures. Considering the wide-ranged timeframe of thrombosis after TMVR, serial echocardiographic follow-up, while balancing individual thromboembolic and haemorrhage risks may guide decisions regarding the extension of anticoagulation until future studies clarify the optimal thromboprophylaxis after TMVR.
Study limitations
This study had the inherent limitations of an observational study without centre-independent adjudication of adverse events. Our findings are subject to potential selection bias and confounding factors including differences in baseline characteristics across the groups. Despite adjustment with available covariates, the residual confounding factors might account for biased outcomes. Several variables that are known to affect the outcomes such as anaemia TMVR for degenerated bioprostheses, failed annuloplasty rings, and severe mitral annular calcification or frailty were not available in the present study. The cumulative rates of cardiovascular mortality and nonfatal outcomes might be overestimated by competing risk of non-cardiovascular and allcause mortality, respectively. Finally, selections of device type and access site were determined at each institution and may have affected the observed outcomes.
Conclusions
The TMVR provided excellent outcomes for patients with degenerated bioprostheses despite high surgical risk. However, ViR and ViMAC were associated with higher rates of adverse events and midterm mortality compared with ViV.
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